Estimations des analystes de Wall Street pour ACADIA Pharmaceuticals Inc. (ACAD): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-11-04 | $0.21 | ||
| 2026-08-04 | $0.18 | $0.07 | +164.1% |
| 2026-05-06 | $0.02 | $0.04 | -50.0% |
| 2026-02-25 | $1.60 | $0.14 | +1067.9% |
| 2025-11-05 | $0.42 | $0.14 | +200.0% |
| 2025-08-06 | $0.16 | $0.14 | +14.3% |
| 2025-05-07 | $0.11 | $0.10 | +10.0% |
| 2025-02-26 | $0.86 | $0.19 | +352.6% |
Ratios de valorisation
| Ratio P/E | 12.24 |
| Prix / Valeur comptable | 3.62 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $17.3M | $124.9M | $223.8M | $339.1M | $441.8M | $484.1M | $517.2M | $726.4M | $957.8M | $1.07B |
| Coût des Ventes | $4.4M | $13.1M | $18.3M | $19.6M | $20.6M | $19.1M | $10.2M | $45.7M | $81.8M | $89.0M |
| Marge Brute | $12.9M | $111.8M | $205.5M | $319.5M | $421.2M | $465.0M | $507.1M | $680.7M | $876.0M | $982.5M |
| R&D | $99.3M | $149.2M | $187.2M | $240.4M | $319.1M | $239.4M | $361.6M | $351.6M | $303.2M | $328.8M |
| Frais Généraux | $186.5M | $255.1M | $265.8M | $325.6M | $388.7M | $396.0M | $369.1M | $402.5M | $488.4M | $548.9M |
| Charges Opérationnelles | $285.7M | $404.3M | $452.9M | $566.0M | $707.8M | $635.4M | $730.7M | $754.1M | $645.2M | $877.7M |
| Résultat Opérationnel | -$272.8M | -$292.4M | -$247.4M | -$246.5M | -$286.6M | -$170.4M | -$223.6M | -$73.4M | $230.8M | $104.8M |
| EBITDA | -$271.0M | -$289.7M | -$244.4M | -$243.8M | -$283.7M | -$164.2M | -$211.4M | -$45.5M | $100.2M | $150.7M |
| Charges d'Intérêt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Résultat Avant Impôts | -$270.1M | -$288.3M | -$243.9M | -$234.4M | -$281.0M | -$167.5M | -$213.4M | -$51.0M | $258.1M | $138.9M |
| Impôts | $1.3M | $1.1M | $1.3M | $876000 | $611000 | $351000 | $2.5M | $10.2M | $31.6M | -$252.1M |
| Résultat Net | -$271.4M | -$289.4M | -$245.2M | -$235.3M | -$281.6M | -$167.9M | -$216.0M | -$61.3M | $226.5M | $391.0M |
| BPA | $-2.34 | $-2.36 | $-1.94 | $-1.60 | $-1.79 | $-1.05 | $-1.34 | $-0.37 | $1.37 | $2.32 |
| BPA Dilué | $-2.34 | $-2.36 | $-1.94 | $-1.60 | $-1.79 | $-1.05 | $-1.34 | $-0.37 | $1.36 | $2.29 |
| Actions en Circulation (Diluées) | $115.9M | $122.6M | $126.6M | $147.2M | $157.3M | $160.5M | $161.7M | $163.8M | $166.4M | $171.4M |
Prix
| Prix | $27.54 |
| Capitalisation | $4.7B |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: ADMA · BLTE · CRNX · DYN · IMVT · LGND · MIRM
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de ACAD: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions